US$ 29.04
tirzepatide biosimilar New Pricing, Access to Available Through Self-Pay Options Tirzepatide, a New Era of
Description
They are not FDA-approved, and the FDA has flagged concerns about variability in purity, potency, and the salt forms some pharmacies use

Insurance coverage and cost often differ between the two brands despite identical formulations
Your Mochi provider may recommend pausing the escalation, dropping back to a previous dose, or extending the time at your current dose before trying to increase again

Small means that the results could be skewed by a few outlier responders

Government insurance beneficiaries (Medicare, Medicaid, TRICARE) are not eligible for the manufacturer savings card
